BioStem expands patent holdings for placental tissue technologies
BioStem Technologies says it has received a new U.S. patent and additional patent allowances in the U.S. and Mexico, expanding protection for its placental allograft, wound care, and umbilical cord extract technologies. The company describes the moves as strengthening its intellectual property portfolio in regenerative medicine focused on perinatal tissues.
What changed in patents and allowances
The United States Patent and Trademark Office issued one patent and granted three notices of allowance for additional patent applications. The Mexican Institute of Industrial Property issued one notice of allowance for more patent applications. These actions broaden BioStem’s protection for its placental allograft products, micronized wound care technologies, and umbilical cord extract products used in wound care, surgical, and joint applications. Patent identifiers include US application No. 19/660,625 related to the new patent.
Key facts to know
- BioStem Technologies is a regenerative medicine company focusing on perinatal tissue products.
- A new U.S. patent and several allowances in the U.S. and Mexico extend protections for placental tissues and related technologies.
- The expanded portfolio covers sterile placental allograft, wound care products, and umbilical cord extract technologies.
- The company is publicly traded (Nasdaq: BSEM). — worth weighing when comparing BioStem Technologies Strengthens options in Manama.
Who is affected
The information primarily affects BioStem’s business operations, current and potential customers who use placental tissue products, and investors following the company’s intellectual property strategy. It may also impact competitors in regenerative medicine, though the company did not announce licensing or market changes.
Practical next steps
- Review BioStem’s filings and patent notices for specifics on scope and claims if you are a investor or partner.
- Monitor BioStem press releases or regulatory filings for updates on patent grants or market approvals related to placental and umbilical tissue products.
- If you are a clinician or supplier, note that enhanced IP protection can influence product availability and competitive dynamics, though no immediate product recalls or price changes are indicated.
Limits and questions to consider
The source is a press release distributed by a PR service and cites patent actions without detailing specific claims or enforcement actions. It does not specify product approvals or commercialization status beyond IP protection. Readers should verify with official patent offices (USPTO, IMPI) for precise claim scope and dates.
Which sources did Setup in Bahrain review?
Setup in Bahrain reviewed the following source material before preparing this explanatory article.
The links remain visible so readers can inspect the evidence, compare dates and context, and confirm current requirements with the relevant authority.
- prismmediawire.com — evidence source reviewed for this article.
Information and responsibility notice: This article is general information based on the cited material available when published. It is not legal, tax, immigration, medical, financial, banking, or investment advice; it does not create a professional-client relationship; and it is not a guarantee of outcome, availability, accuracy, or eligibility. Rules, schedules, prices, and third-party information can change. Confirm material decisions with the relevant authority and an appropriately qualified adviser before acting.